FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Methotrexate Sodium Injection
Status: Currently in Shortage
»Date first posted: 04/24/2017
»Therapeutic Categories: Oncology

Expand all

Accord Healthcare Inc. (Revised 10/26/2017)

Company Contact Information:
800-843-7477

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
25 mg/mL; 2mL (NDC 16729-277-30) Available Available
25 mg/mL; 40 mL (NDC 16729-277-35) Available Available
25 mg/mL; 10 mL (NDC 16729-277-03) Available Available

Fresenius Kabi USA, LLC (Reverified 11/17/2017)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
1 gram per vial, 50 mL vial, SDV (NDC 63323-122-50) Available Check wholesalers for inventory. Demand increase for the drug
250 mg per 10 mL, vial (NDC 63323-123-10) Available Check wholesalers for inventory. Demand increase for the drug

Hospira, Inc. (Revised 11/13/2017)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
25 mg/mL; 50 mg/2 mL Glass Fliptop Vial (NDC 61703-0350-38) Available Available Other
25 mg/mL; 1 g/40 mL Single Dose Glass Fliptop Vial (Preservative Free)(NDC 61703-0408-41) Available Available Other

Mylan Institutional (Reverified 11/08/2017)

Company Contact Information:
800-496-9526

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
1000 mg/40 mL (NDC 67457-480-40) Available Available Demand increase for the drug

Teva Pharmaceuticals (Revised 10/25/2017)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
25MG/ML 1X40ML (NDC 00703-3678-01) Teva has limited inventory and product is being allocated. Limited supply on allocation is projected until demand stabilizes. Overall full recovery is expected in Q1-2018. Demand increase for the drug
25MG/ML 1X40ML Premier label (NDC 00703-3678-81) Teva has limited inventory and product is being allocated. Limited supply on allocation is projected until demand stabilizes. Overall full recovery is expected in Q1-2018. Demand increase for the drug
25MG/ML 1X10ML (NDC 00703-3675-01) Teva has limited inventory and product is being allocated. Limited supply on allocation is projected until demand stabilizes. Overall full recovery is expected in Q1-2018. Demand increase for the drug
25MG/ML SDV 10X2ML (NDC 00703-3671-03) Teva has limited inventory and product is being allocated. Limited supply on allocation is projected until demand stabilizes. Overall full recovery is expected in Q1-2018. Demand increase for the drug

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English